source
- Amgen files update to Tavneos label as FDA escalates push to withdrawAmgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA. The company filed a supplement on Wednesday that would add more information to the warning ...Endpoints · 3mo ago↗ source
- Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutA trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined. Seaport Therapeutics, Hemab Therapeutic…Endpoints · 3mo ago↗ source
- J&J axes pair of CAR-T therapies for lymphoma, citing evolving marketJohnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease. The drugmaker